New Developments in Colon Cancer Treatment
Today we have more options in the treatment of colon cancer; however, the important thing is to determine which of these options will benefit which patient. The stage of the disease, the pathology result and the person's general health are evaluated together. The collaborative work of surgical, medical oncology, radiology and pathology specialists determines both the surgical plan and the timing and scope of drug treatment. In some patients with limited spread to the liver or lungs, surgical or regional treatments targeting metastases may also be considered. [1]
One of the important steps in personalized treatment is recognizing the molecular characteristics of the tumor. MMR/MSI analysis provides information about the ability of cancer cells to repair certain errors in DNA. In metastatic disease, the evaluation of targets such as RAS, BRAF and, if necessary, HER2 guides drug selection. These results become meaningful whether the tumor originates from the right or left colon and in conjunction with previous treatments. [1]
One of the significant developments in postoperative treatment in 2026 was the ATOMIC study. In stage III colon cancer with lymph node metastasis and DNA repair defect (dMMR), adding the immunotherapy atezolizumab to standard FOLFOX chemotherapy extended disease-free survival. This approach was approved in the US in 2026. The results are specific to this particular molecular group, not all stage III patients. [2,3]
In inoperable or metastatic disease, the detection of dMMR or high microsatellite instability (MSI-H) can alter the choice of treatment. The combination of pembrolizumab with nivolumab and ipilimumab is among the options that can provide long-term disease control in suitable patients. This dual therapy was approved in the US in 2025. In contrast, immunotherapy is often not a standard option in tumors that do not have these characteristics. [1,4]
Targeted drugs are also expanding their areas of use. In metastatic disease with BRAF V600E mutation, the combination of encorafenib, cetuximab, and fluorouracil-based chemotherapy received full approval in the US in 2026. In patients with KRAS G12C mutation who have previously received the necessary chemotherapy, sotorasib with panitumumab; and in suitable patients who are HER2 positive, do not have RAS mutations, and have progressed after previous treatments, tukatinib with trastuzumab can be options. These drugs are evaluated when the relevant target is identified. [5–7]
The investigation of circulating tumor DNA (ctDNA) in the blood after surgery is also a closely monitored area. This test can provide information about any remaining microscopic disease and the risk of recurrence. However, the DYNAMIC-III results showed that reducing or intensifying chemotherapy based solely on ctDNA results does not always lead to better outcomes in stage III disease. Therefore, the test should not be considered a standalone decision-making tool replacing standard assessments. [8]
New treatments offer hope; however, the benefits they provide to the patient depend on the right choice and regular follow-up. The side effects of the treatment, its impact on bowel function, nutrition, and daily life should be openly discussed. Each option should be evaluated considering the patient's priorities, along with accessibility conditions in Türkiye.
Sources [1] NCI · Colon cancer | [2] ATOMIC · NEJM 2026 | [3] Atezolizumab · FDA 2026 | [4] CheckMate-8HW · FDA | [5] BRAF · FDA 2026 | [6] KRAS G12C · FDA | [7] HER2 · FDA | [8] DYNAMIC-III
